Blood purification could tackle COVID-19?

Journal of Intensive Care

Shigeru Ohtsuru¹  Hiroyuki Yamada² 

[1] Department of Primary Care and Emergency Medicine, Graduate School of Medicine, Kyoto University, 54 Shogoin-kawaharacho, Sakyo-ku, 6068507, Kyoto, Japan;Department of Primary Care and Emergency Medicine, Graduate School of Medicine, Kyoto University, 54 Shogoin-kawaharacho, Sakyo-ku, 6068507, Kyoto, Japan;Department of Nephrology, Graduate School of Medicine, Kyoto University, Kyoto, Japan;

关键词: Plasmapheresis;    Plasma exchange;    Cytosorb;    Apheresis;    AN69ST;    Oxiris;    PMX-DHP;    Coronavirus;    Pandemic;    Cytokine;   

DOI  :  10.1186/s40560-021-00586-0

来源: Springer

【 摘 要 】

Coronavirus disease 2019 (COVID-19) threatened human lives worldwide since first reported. The current challenge for global intensivists is to establish an effective treatment for severe COVID-19. Blood purification has been applied to the treatment of various critical illnesses. Theoretically, its technique also has an enormous possibility of treating severe COVID-19 in managing inflammatory cytokines and coagulopathy. Recent clinical studies have revealed the positive clinical effect of therapeutic plasma exchange. Other studies have also indicated the considerable potential of other blood purification techniques, such as Cytosorb, AN69 surface-treated membrane, and polymyxin b hemoperfusion. Further research is needed to elucidate the actual effects of these applications.

【 授权许可】

CC BY